NCT02532114View on ClinicalTrials.gov

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Interventions
DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Niclosamide

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02532114 - Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter